| Title |
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, October 2018
|
| DOI | 10.1007/s00228-018-2576-4 |
| Pubmed ID | |
| Authors |
Matthew P. Kosloski, Haoyu Wang, David Pugatch, Federico J. Mensa, Edward Gane, Eric Lawitz, Thomas C. Marbury, Richard A. Preston, Jens Kort, Wei Liu |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 38% |
| Student > Bachelor | 2 | 13% |
| Student > Master | 2 | 13% |
| Student > Ph. D. Student | 1 | 6% |
| Professor > Associate Professor | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 4 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Immunology and Microbiology | 1 | 6% |
| Unknown | 6 | 38% |